← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Kuda Therapeutics, Inc.
Salt Lake City, UT
$8,984,141
Total funding
5
Grants
Funding over time
peak $6M · FY2018–25$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$6,579,141 · 3
NIH$2,405,000 · 2
By mechanism
—$6,579,141 · 3
R44$2,050,000 · 1
R43$355,000 · 1
Investigators at Kuda Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
ADVANCING A NOVEL, ORALLY AVAILABLE FERROPTOSIS INDUCER FOR THE TREATMENT OF VHL DISEASE$5,599,141
· FY2025 · Defense Health Agency
Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer$1,425,000
R44 · FY2022 · CA
Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer$625,000
R44 · FY2023 · CA
THE INVESTIGATION OF FERROPTOSIS AS A NOVEL THERAPEUTIC PARADIGM FOR KIDNEY CANCER$560,000
· FY2020 · Defense Health Agency
FERROPTOSIS AS A THERAPEUTIC STRATEGY FOR CLEAR CELL OVARIAN CANCER$420,000
· FY2025 · Defense Health Agency
Development of a novel class of selective HIF-2A inhibitors for kidney cancer$180,074
R43 · FY2018 · CA
Development of a novel class of selective HIF-2A inhibitors for kidney cancer$119,926
R43 · FY2018 · CA
Development of a novel class of selective HIF-2A inhibitors for kidney cancer$55,000
R43 · FY2019 · CA